Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study

[Background/Objectives] Ibrutinib is a selective Bruton’s tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL). This drug exhibits significant variability in response and toxicity profile, possibly due to genetic polymorphisms in drug-metabolizing enzymes and tr...

Descripción completa

Detalles Bibliográficos
Autores: Pérez-Gómez, Noelia, Sanz-Solas, Antonio, Cuevas, Beatriz, Cuevas, María Victoria, Alonso-Madrigal, Cristina, Loscertales, Javier, Álvarez-Nuño, Rodolfo, García, Covadonga, Zubiaur, Pablo, Villapalos-García, Gonzalo, Parra-Garcés, Raúl Miguel, Mejía-Abril, Gina, Alcaraz, Raquel, Vinuesa, Raquel, Díaz-Gálvez, Francisco Javier, González-Oter, María, García-Sancha, Natalia, Azibeiro-Melchor, Raúl, González-López, Tomás José, Abad-Santos, Francisco, Labrador, Jorge, Saiz-Rodríguez, Miriam
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/399918
Acceso en línea:http://hdl.handle.net/10261/399918
Access Level:acceso abierto
Palabra clave:Chronic lymphocytic leukemia
Ibrutinib
Pharmacogenetics
Polymorphisms
Descripción
Sumario:[Background/Objectives] Ibrutinib is a selective Bruton’s tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL). This drug exhibits significant variability in response and toxicity profile, possibly due to genetic polymorphisms in drug-metabolizing enzymes and transporters. The aim of this observational study is to address interindividual variability in the efficacy and safety of ibrutinib treatment in 49 CLL patients

Similares en LA Referencia